Page last updated: 2024-11-01

nortriptyline and Gastric Stasis

nortriptyline has been researched along with Gastric Stasis in 1 studies

Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.

Research Excerpts

ExcerptRelevanceReference
"To determine whether treatment with nortriptyline results in symptomatic improvement in patients with idiopathic gastroparesis."9.17Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. ( Abell, TL; Farrugia, G; Hamilton, F; Hasler, WL; Koch, KL; Lee, L; McCallum, RW; Nguyen, L; Parkman, HP; Pasricha, PJ; Sarosiek, I; Snape, WJ; Tonascia, J; Unalp-Arida, A; Van Natta, ML, 2013)
"To determine whether treatment with nortriptyline results in symptomatic improvement in patients with idiopathic gastroparesis."5.17Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. ( Abell, TL; Farrugia, G; Hamilton, F; Hasler, WL; Koch, KL; Lee, L; McCallum, RW; Nguyen, L; Parkman, HP; Pasricha, PJ; Sarosiek, I; Snape, WJ; Tonascia, J; Unalp-Arida, A; Van Natta, ML, 2013)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Parkman, HP1
Van Natta, ML1
Abell, TL1
McCallum, RW1
Sarosiek, I1
Nguyen, L1
Snape, WJ1
Koch, KL1
Hasler, WL1
Farrugia, G1
Lee, L1
Unalp-Arida, A1
Tonascia, J1
Hamilton, F1
Pasricha, PJ1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG)[NCT00765895]Phase 3130 participants (Actual)Interventional2009-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits

A decrease from the baseline Gastroparesis Cardinal Symptom Index (GCSI) score (sum of the 9 individual symptom scores) of at least 50% on any two consecutive follow-up visits during the 15 week treatment period with maximum tolerated study drug dose. The total score ranges from 0-45 with higher scores indicating greater symptom severity. (NCT00765895)
Timeframe: at end of treatment, 15 weeks from baseline assessment

Interventionparticipants (Number)
Nortriptyline15
Placebo14

Trials

1 trial available for nortriptyline and Gastric Stasis

ArticleYear
Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial.
    JAMA, 2013, Dec-25, Volume: 310, Issue:24

    Topics: Adrenergic Uptake Inhibitors; Double-Blind Method; Female; Gastroparesis; Humans; Male; Nortriptylin

2013